SCHEMBL8281139

SCHEMBL8281139

C[C@H](O)c1cccc(N)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 5/20 0.50
CASP1 P29466 1/20 0.50
RECQL P46063 1/20 0.50
MEN1 O00255 1/20 0.48
KMT2A Q03164 1/20 0.48
UGT2B7 P16662 1/20 0.48
CPN1 P15169 1/20 0.47
CPB2 Q96IY4 1/20 0.47
ALDH1A1 P00352 4/20 0.46
CA1 P00915 2/20 0.46
CA2 P00918 2/20 0.46
CA9 Q16790 2/20 0.46
CA12 O43570 1/20 0.46
CA7 P43166 1/20 0.46
TDP1 Q9NUW8 1/20 0.46
CA14 Q9ULX7 1/20 0.46
ADRB1 P08588 1/20 0.44
MIF P14174 1/20 0.44
HTR2A P28223 1/20 0.44
ADRA1A P35348 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL297422 1.00 CYP3A4 (0.50) CYP3A4CASP1RECQLMEN1KMT2A
SCHEMBL30074145 1.00 CYP3A4 (0.50) CYP3A4CASP1RECQLMEN1KMT2A
SCHEMBL8281143 1.00 CYP3A4 (0.50) CYP3A4CASP1RECQLMEN1KMT2A
SCHEMBL29687003 1.00 CYP3A4 (0.50) CYP3A4CASP1RECQLMEN1KMT2A
Hydrochloric Acid SCHEMBL4983488 0.98 CYP3A4 (0.48) CYP3A4CASP1RECQLMEN1KMT2A
SCHEMBL2812852 0.85 UGT2B7 (0.56) CYP3A4MEN1KMT2AUGT2B7ALDH1A1
SCHEMBL9331659 0.85 UGT2B7 (0.56) CYP3A4MEN1KMT2AUGT2B7ALDH1A1
SCHEMBL9331663 0.85 UGT2B7 (0.56) CYP3A4MEN1KMT2AUGT2B7ALDH1A1
SCHEMBL9334664 0.85 UGT2B7 (0.56) CYP3A4MEN1KMT2AUGT2B7ALDH1A1
SCHEMBL272384 0.83 CYP3A4 (0.52) CYP3A4CASP1RECQLMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-105039445-A Method for producing (S)-aminophenethylalcohol through cells UNIV QINGDAO SCIENCE & TECHNOLOGY 2015-11-11 CN claimed
CN-109983014-B Mutant isocitrate dehydrogenase inhibitors, compositions and methods thereof 艾科生物科技有限公司 2022-12-23 CN disclosed
WO-2022221704-A1 COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING CANCER HOTSPOT THERAPEUTICS, INC. (US) 2022-10-20 WO disclosed
US-20210101899-A1 INHIBITORS OF MUTANT ISOCITRATE DEHYDROGENASES AND COMPOSITIONS AND METHODS THEREOF ISOCURE BIOSCIENCES INC (US) 2021-04-08 US disclosed
US-10781207-B2 Inhibitors of mutant isocitrate dehydrogenases and compositions and methods thereof ISOCURE BIOSCIENCES INC. (US) 2020-09-22 US disclosed
US-10781207-B2 Inhibitors of mutant isocitrate dehydrogenases and compositions and methods thereof ISOCURE BIOSCIENCES INC. (US) 2020-09-22 US disclosed
US-20190233414-A1 INHIBITORS OF MUTANT ISOCITRATE DEHYDROGENASES AND COMPOSITIONS AND METHODS THEREOF ISOCURE BIOSCIENCES INC (US) 2019-08-01 US disclosed
US-20190233414-A1 INHIBITORS OF MUTANT ISOCITRATE DEHYDROGENASES AND COMPOSITIONS AND METHODS THEREOF ISOCURE BIOSCIENCES INC (US) 2019-08-01 US disclosed
WO-2019023165-A1 INHIBITORS OF MUTANT ISOCITRATE DEHYDROGENASES AND COMPOSITIONS AND METHODS THEREOF ISOCURE BIOSCIENCES INC. (US) 2019-01-31 WO disclosed
WO-2018071404-A1 INHIBITORS OF MUTANT ISOCITRATE DEHYDROGENASES AND COMPOSITIONS AND METHODS THEREOF ISOCURE BIOSCIENCES INC. (US) 2018-04-19 WO disclosed
CN-105039445-A Method for producing (S)-aminophenethylalcohol through cells UNIV QINGDAO SCIENCE & TECHNOLOGY 2015-11-11 CN disclosed
WO-2005103055-A1 PYRAZOLO-[4,3-e]-1,2,4-TRIAZOLO-[1,5-c]-PYRIMIDINE ADENOSINE A2A RECEPTOR ANTAGONISTS SCHERING CORPORATION (US) 2005-11-03 WO disclosed
US-5610144-A CHOLECYSTOKININ OR GASTRIN ANTAGONISTS; NERVOUS SYSTEM AND GASTROINTESTINAL DISORDERS RHONE-POULENC RORER S.A. (FR) 1997-03-11 US disclosed
US-5382590-A Gastrointestinal disorders and nervous system disorders RHONE-POULENC RORER S.A. (FR) 1995-01-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210101899-A1 INHIBITORS OF MUTANT ISOCITRATE DEHYDROGENASES AND COMPOSITIONS AND METHODS THEREOF IDH1, IDH2, IDH3A CYP3A4 1151/4885CASP1 4240/4885RECQL 217/4885
US-10781207-B2 Inhibitors of mutant isocitrate dehydrogenases and compositions and methods thereof IDH1, IDH2, IDH3A CYP3A4 1151/4885CASP1 4240/4885RECQL 217/4885
US-20190233414-A1 INHIBITORS OF MUTANT ISOCITRATE DEHYDROGENASES AND COMPOSITIONS AND METHODS THEREOF IDH1, IDH2, IDH3A CYP3A4 1151/4885CASP1 4240/4885RECQL 217/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.